Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by prophetoffactzon Jan 18, 2023 7:08am
104 Views
Post# 35229940

RE:Sadly, I Think It's Checkmate

RE:Sadly, I Think It's Checkmate"However, there may be some upside to Biodexa and pursuing that may turn out to be good. If the stock has a run on news, and there could be some very strong news, then you might find an exit point, or good reason to continue to hold."

One billion shares but $10 tens-of-billions in potential revenue?

Early-stage biotech is incredibly risky but the market opportunities are there.

Biodexa could have two major plarform technologies validated by the world's largest healthcare company too. Both Q-Sphera and xB3 can work with already approved drugs. Midatech's lead cancer drug is also FDA approved and significantly de-risked for brain cancer in human clinical trials.

Like Midatech's CEO do you defy anyone to find a company this size with the opportunity set of Biodexa? Is there an indication a fund like Armitage Capital agrees? Ladenberg Thalmann? Is Biodexa a potential 'Saltarelli' on steroids?



<< Previous
Bullboard Posts
Next >>